Loading...
Dyslipidemia is common in HIV-infected patients, but treatment outcomes are often unsatisfactory. In this study from Kaiser Permanente in California, investigators compared responses to lipid-lowering therapy between 829 HIV-infected patients and 6941 uninfected controls, all with laboratory evidence of dyslipidemia.
The HIV-infected patients had significantly smaller LDL declines in response to statin therapy than their HIV-negative counterparts (reduction, 25.6% vs. 28.3%); within the HIV population, pravastatin was less effective than other agents (simvastatin, lovastatin, or atorvastatin). Response to fibrate therapy (gemfibrozil) was also worse among HIV-infected patients, particularly those receiving PIs. Three cases of rhabdomyolysis …